Vertex Pharmaceuticals Inc (NASDAQ:VRTX)

120.17
Delayed Data
As of Mar 02
 +0.74 / +0.62%
Today’s Change
59.79
Today|||52-Week Range
127.69
+1.15%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$28.9B

Company Description

Vertex Pharmaceuticals, Inc. is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The company's research focuses on cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis. Its product pipe line includes NCIVEK (telaprevir), which is marketed in the U.S. and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection; and KALYDECO (ivacaftor), which it markets in the U.S., Canada and Europe for the treatment of patients six years of age and older with cystic fibrosis, or CF, who have a specific genetic mutation that is referred to as the G551D mutation. The company's other drug candidates include ivacaftor, VX-809, VX-661, VX-135, VX-222, VX-509 and VX-787. Vertex Pharmaceuticals was founded by Boger S. Joshua in 1989 and is headquartered in Cambridge, MA.

Contact Information

Vertex Pharmaceuticals, Inc.
130 Waverly Street
Cambridge Massachusetts 02139-4242
P:(617) 444-6100
Investor Relations:
(617) 444-6108

Employees

Shareholders

Mutual fund holders65.10%
Other institutional31.33%
Individual stakeholders1.23%

Top Executives

Jeff M. LeidenChairman, President & Chief Executive Officer
Ian F. SmithChief Financial Officer & Executive Vice President
Jeffrey A. ChodakewitzChief Medical Officer & Senior Vice President
David Matthew AltshulerChief Scientific Officer & EVP-Global Research
Stuart A. ArbuckleChief Commercial Officer & Executive VP

To view my watchlist

Not a member yet?

Sign up now for a free account